Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARTON G WILLIAMS

Allopathic & Osteopathic Physicians Family Medicine

NPI
1265540751
CMS profile
12422
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,108.78

155 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,108.78 155

By paying entity

PY2020 · entire year · sorted by reported total

Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARTON G WILLIAMS

NPI 1265540751 · CMS profile ID 12422

Allopathic & Osteopathic Physicians / Family Medicine

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265540751?year=2020&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARTON G WILLIAMS, NPI 1265540751, CMS profile ID 12422. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265540751?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). BARTON G WILLIAMS, NPI 1265540751, CMS profile ID 12422. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265540751?year=2020&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
BARTON G WILLIAMS, NPI 1265540751, CMS profile ID 12422, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–155 of 155 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1265540751?year=2020&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

155 matching records · $2,108.78 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 155 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–155 of 155.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Currax Pharmaceuticals LLC $12.5901/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739141255 CMS
Amgen Inc. $15.9601/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740927955 CMS
Amarin Pharma Inc. $20.2101/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739798377 CMS
Novo Nordisk Inc $15.5701/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744555403 CMS
Merck Sharp & Dohme Corporation $9.4401/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747678199 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,826.36 111
PY2020 $2,108.78 155
PY2021 $2,337.03 185
PY2022 $2,053.32 135
PY2023 $1,637.42 105
PY2024 $2,128.76 107
PY2025 $2,333.98 104

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,195,470.42 222
PY2024 Principal investigator $3,547,601.63 105
PY2023 Principal investigator $4,081,133.60 1,771
PY2022 Principal investigator $5,076,589.95 1,727
PY2021 Principal investigator $2,362,774.52 85

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

222 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $18,350.00 12/31/2025 Non-covered Recipient Entity
TMA Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228736882
Principal investigator 1 PFIZER INC. $11,746.00 12/23/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228732754
Principal investigator 1 PFIZER INC. $351.00 12/22/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228724000
Principal investigator 1 ModernaTX, Inc. $8,800.00 12/19/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
Post marketing commitment study to assess clinical efficacy & safety of current JN.1-based formulation with focus on lower-risk adults (50-64 years) to inform benefit-risk profile (PMC2) No dispute reported 06/30/2026 1252946584
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290848
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290850
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290852
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290854
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290856
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290858
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290860
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185290862
Principal investigator 1 Seqirus USA Inc $1,253.00 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291018
Principal investigator 1 Seqirus USA Inc $1,253.00 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291020
Principal investigator 1 Seqirus USA Inc $1,253.00 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291022
Principal investigator 1 Seqirus USA Inc $1,253.00 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291024
Principal investigator 1 Seqirus USA Inc $1,253.00 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291026
Principal investigator 1 Seqirus USA Inc $1,253.00 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291028
Principal investigator 1 Seqirus USA Inc $1,253.00 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291030
Principal investigator 1 Seqirus USA Inc $487.20 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291032
Principal investigator 1 Seqirus USA Inc $487.20 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291034
Principal investigator 1 Seqirus USA Inc $487.20 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291040
Principal investigator 1 Seqirus USA Inc $1,253.00 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291046
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291052
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291056
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291058
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291060
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291062
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291064
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291066
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291068
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291070
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291072
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291074
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291076
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291078
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291080
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291082
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291084
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291086
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291088
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291090
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291092
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291094
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291096
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291098
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291100
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291102
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291104
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291106
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291108
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291110
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291112
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291114
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291116
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291118
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291120
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291122
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291124
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291126
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291128
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291130
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291134
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291136
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291138
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291140
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291143
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291146
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291148
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291150
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291152
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291154
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291156
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291158
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291160
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291162
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291164
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291166
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291168
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291170
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291172
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291174
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291176
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291178
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291180
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291183
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291186
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291188
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291190
Principal investigator 1 Seqirus USA Inc $3,529.40 12/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291192
Principal investigator 1 PFIZER INC. $24,960.25 12/17/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228745898
Principal investigator 1 PFIZER INC. $36,706.25 12/16/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228738330
Principal investigator 1 ModernaTX, Inc. $925.30 11/27/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961059
Principal investigator 1 ModernaTX, Inc. $2,836.79 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995877
Principal investigator 1 ModernaTX, Inc. $3,880.36 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995881
Principal investigator 1 ModernaTX, Inc. $2,064.04 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995883
Principal investigator 1 ModernaTX, Inc. $1,796.96 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995887
Principal investigator 1 ModernaTX, Inc. $5,100.40 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995891
Principal investigator 1 ModernaTX, Inc. $5,598.55 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995893
Principal investigator 1 ModernaTX, Inc. $303.00 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995895
Principal investigator 1 ModernaTX, Inc. $3,535.56 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995897
Principal investigator 1 ModernaTX, Inc. $3,403.40 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995901
Principal investigator 1 ModernaTX, Inc. $4,028.25 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995903
Principal investigator 1 ModernaTX, Inc. $5,432.50 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995905
Principal investigator 1 ModernaTX, Inc. $13.81 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995907
Principal investigator 1 ModernaTX, Inc. $5,057.80 11/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995909
Principal investigator 1 PFIZER INC. $3,182.54 11/20/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228728213
Principal investigator 1 PFIZER INC. $14,682.50 11/11/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228728874
Principal investigator 1 ModernaTX, Inc. $165.00 11/06/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995885
Principal investigator 1 ModernaTX, Inc. $500.00 11/06/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995889
Principal investigator 1 ModernaTX, Inc. $7,466.94 11/06/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010760
Principal investigator 1 PFIZER INC. $16,452.82 11/04/2025 Non-covered Recipient Entity
TMA Headlands LLC
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228712996
Principal investigator 1 Seqirus USA Inc $4,274.00 11/03/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809442
Principal investigator 1 Seqirus USA Inc $1,174.50 11/03/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809446
Principal investigator 1 PFIZER INC. $1,468.25 10/30/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228730618
Principal investigator 1 ModernaTX, Inc. $22,207.20 10/27/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961031
Principal investigator 1 ModernaTX, Inc. $16,056.90 10/27/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961041
Principal investigator 1 ModernaTX, Inc. $500.00 10/22/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995879
Principal investigator 1 PFIZER INC. $19,087.25 10/11/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228740692
Principal investigator 1 Seqirus USA Inc $750.00 10/09/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291042
Principal investigator 1 Seqirus USA Inc $1,500.00 10/09/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291048
Principal investigator 1 Seqirus USA Inc $2,500.00 10/09/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291050
Principal investigator 1 Seqirus USA Inc $9,500.00 10/09/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291054
Principal investigator 1 Seqirus USA Inc $1,500.00 10/09/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291194
Principal investigator 1 Seqirus USA Inc $1,500.00 10/09/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291196
Principal investigator 1 ModernaTX, Inc. $2,776.90 10/06/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010748
Principal investigator 1 ModernaTX, Inc. $1,850.60 09/29/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961057
Principal investigator 1 ModernaTX, Inc. $594.70 09/29/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961061
Principal investigator 1 PFIZER INC. $38,174.50 09/27/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228751083
Principal investigator 1 PFIZER INC. $13,214.25 09/24/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228757121
Principal investigator 1 Seqirus USA Inc $110.98 09/10/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291036
Principal investigator 1 Seqirus USA Inc $111.30 09/10/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291038
Principal investigator 1 Seqirus USA Inc $946.80 09/10/2025 Non-covered Recipient Entity
Trial Management Associates LLC - Ern - Ppds
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185291044
Principal investigator 1 PFIZER INC. $22,023.75 09/09/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228750651
Principal investigator 1 ModernaTX, Inc. $297.35 08/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961039
Principal investigator 1 ModernaTX, Inc. $217.36 08/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010740
Principal investigator 1 PFIZER INC. $75.00 08/21/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228720755
Principal investigator 1 ModernaTX, Inc. $1,200.00 08/06/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961049
Principal investigator 1 PFIZER INC. $199.32 08/04/2025 Non-covered Recipient Entity
Trial Management Assoc LLC
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713166
Principal investigator 1 PFIZER INC. $757.50 08/04/2025 Non-covered Recipient Entity
Trial Management Assoc LLC
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713168
Principal investigator 1 PFIZER INC. $131.75 08/04/2025 Non-covered Recipient Entity
Trial Management Assoc LLC
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228713170
Principal investigator 1 PFIZER INC. $76,349.00 08/01/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228753348
Principal investigator 1 PFIZER INC. $24,134.60 07/26/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228771908
Principal investigator 1 ModernaTX, Inc. $221.00 07/23/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002453
Principal investigator 1 ModernaTX, Inc. $326.03 07/23/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010736
Principal investigator 1 PFIZER INC. $3,412.80 07/18/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228712998
Principal investigator 1 ModernaTX, Inc. $54,821.65 07/16/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961029
Principal investigator 1 ModernaTX, Inc. $6,000.00 07/16/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961043
Principal investigator 1 ModernaTX, Inc. $19,407.70 07/09/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961023
Principal investigator 1 ModernaTX, Inc. $119,445.96 07/09/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961037
Principal investigator 1 ModernaTX, Inc. $2,800.05 07/09/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961045
Principal investigator 1 ModernaTX, Inc. $18,368.10 07/09/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961047
Principal investigator 1 PFIZER INC. $144,756.17 07/08/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228763949
Principal investigator 1 ModernaTX, Inc. $1,163.70 07/07/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961035
Principal investigator 1 ModernaTX, Inc. $3,701.10 07/07/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961055
Principal investigator 1 ModernaTX, Inc. $5,506.80 07/07/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961063
Principal investigator 1 ModernaTX, Inc. $1,028.70 07/07/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961065
Principal investigator 1 PFIZER INC. $30,174.08 07/01/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228762816
Principal investigator 1 ModernaTX, Inc. $4,977.96 06/25/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010746
Principal investigator 1 ModernaTX, Inc. $15,909.08 06/18/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010738
Principal investigator 1 PFIZER INC. $83,241.89 06/10/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228722826
Principal investigator 1 PFIZER INC. $1,776.25 05/30/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228782466
Principal investigator 1 ModernaTX, Inc. $14,301.30 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961027
Principal investigator 1 ModernaTX, Inc. $26,833.70 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961033
Principal investigator 1 ModernaTX, Inc. $8,517.78 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010756
Principal investigator 1 ModernaTX, Inc. $27,051.44 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010758
Principal investigator 1 ModernaTX, Inc. $107,176.96 05/28/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010768
Principal investigator 1 PFIZER INC. $363.05 05/27/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707744
Principal investigator 1 PFIZER INC. $363.05 05/27/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228760349
Principal investigator 1 ModernaTX, Inc. $46.79 05/23/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010762
Principal investigator 1 PFIZER INC. $211.65 05/16/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228719390
Principal investigator 1 PFIZER INC. $184.50 05/16/2025 Non-covered Recipient Entity
Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228723750
Principal investigator 1 PFIZER INC. $43,895.28 05/15/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228771354
Principal investigator 1 ModernaTX, Inc. $326.03 05/09/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010770
Principal investigator 1 PFIZER INC. $7,126.26 05/08/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228723276
Principal investigator 1 PFIZER INC. $35.00 05/07/2025 Non-covered Recipient Entity
TMA Headlands LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228776764
Principal investigator 1 ModernaTX, Inc. $158.08 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002455
Principal investigator 1 ModernaTX, Inc. $31,231.86 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002457
Principal investigator 1 ModernaTX, Inc. $36,516.48 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010754
Principal investigator 1 ModernaTX, Inc. $34,330.12 05/01/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010764
Principal investigator 1 PFIZER INC. $47,579.84 03/28/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228783890
Principal investigator 1 ModernaTX, Inc. $33,196.80 03/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002451
Principal investigator 1 ModernaTX, Inc. $32,651.49 03/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002461
Principal investigator 1 ModernaTX, Inc. $10,466.50 03/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010744
Principal investigator 1 ModernaTX, Inc. $2,776.90 03/24/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010750
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707748
Principal investigator 1 PFIZER INC. $189.80 03/24/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228770224
Principal investigator 1 PFIZER INC. $53,967.40 03/22/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228795130
Principal investigator 1 PFIZER INC. $39,712.18 03/20/2025 Non-covered Recipient Entity
TMA Headlands LLC dba Trial Management Associates
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228788489
Principal investigator 1 ModernaTX, Inc. $208.00 03/10/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES, LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961021
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707746
Principal investigator 1 PFIZER INC. $189.80 03/10/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228760753
Principal investigator 1 ModernaTX, Inc. $5,967.00 03/05/2025 Non-covered Recipient Entity
TMA HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002459
Principal investigator 1 ModernaTX, Inc. $104.00 02/28/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961019
Principal investigator 1 ModernaTX, Inc. $37,148.80 02/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002467
Principal investigator 1 ModernaTX, Inc. $1,033.70 02/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002469
Principal investigator 1 ModernaTX, Inc. $48,983.22 02/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010742
Principal investigator 1 ModernaTX, Inc. $41,169.27 02/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010766
Principal investigator 1 ModernaTX, Inc. $61,376.40 02/26/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961025
Principal investigator 1 ModernaTX, Inc. $234.90 02/26/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961051
Principal investigator 1 PFIZER INC. $3,201.50 02/25/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228751697
Principal investigator 1 PFIZER INC. $317.00 02/24/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707926
Principal investigator 1 PFIZER INC. $726.10 02/24/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707928
Principal investigator 1 PFIZER INC. $317.00 02/24/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228760757
Principal investigator 1 PFIZER INC. $726.10 02/24/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228770220
Principal investigator 1 ModernaTX, Inc. $83.20 02/19/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ?18 to <65 Years of Age No dispute reported 06/30/2026 1252961017
Principal investigator 1 PFIZER INC. $2,350.00 02/19/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707826
Principal investigator 1 PFIZER INC. $317.00 02/19/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707828
Principal investigator 1 PFIZER INC. $726.10 02/19/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228707830
Principal investigator 1 PFIZER INC. $317.00 02/19/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228761530
Principal investigator 1 PFIZER INC. $726.10 02/19/2025 Non-covered Recipient Entity
Trial Management Associates Wilmington Floral Parkway
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228769892
Principal investigator 1 PFIZER INC. $981.24 02/07/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228785579
Principal investigator 1 PFIZER INC. $837.08 02/07/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228786739
Principal investigator 1 PFIZER INC. $981.24 02/03/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228785584
Principal investigator 1 PFIZER INC. $837.08 02/03/2025 Non-covered Recipient Entity
Trial Management Associates LLC
A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1228786735
Principal investigator 1 ModernaTX, Inc. $45,858.15 01/30/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252995899
Principal investigator 1 ModernaTX, Inc. $36,674.56 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002447
Principal investigator 1 ModernaTX, Inc. $35,145.80 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002449
Principal investigator 1 ModernaTX, Inc. $28,887.54 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002463
Principal investigator 1 ModernaTX, Inc. $31,231.86 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253002465
Principal investigator 1 ModernaTX, Inc. $1,970.44 01/27/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010752
Principal investigator 1 ModernaTX, Inc. $500.00 01/24/2025 Non-covered Recipient Entity
TRIAL MANAGEMENT ASSOCIATES LLC
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age No dispute reported 06/30/2026 1252961053